Ovarian cancer mortality is reduced by up to 96% if a risk-reducing salpingo-oophorectomy [RRSO] is performed before ovarian incidence rises [age 35–40 years for BRCA1 carriers and age 40–45 years for BRCA2 GPV carriers] [5,6]. This evidence concerns the gene BRCA2 and ovarian carcinoma.